title: Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registry.
abstract: BACKGROUND
  Type-2 diabetes mellitus has a major impact on health related quality of life (HRQoL). We aimed to identify patient and treatment related variables having a major impact.
  
  
  METHODS
  DiaRegis is a prospective diabetes registry. The EQ-5D was used to describe differences in HRQoL at baseline. Odds ratios (OR) with 95% confidence intervals (CI) were determined from univariable regression analysis. For the identification of independent predictors of a low score on the EQ-5D, multivariable unconditional logistic regression analysis was performed.
  
  
  RESULTS
  A total of 2,760 patients were available for the present analysis (46.7% female, median age 66.2 years). Patients had considerable co-morbidity (18.3% coronary artery disease, 10.6% heart failure, 5.9% PAD and 5.0% stroke/TIA). Baseline HbA1c was 7.4%, fasting- and postprandial plasma glucose 139 mg/dl and 183 mg/dl.The median EQ-5D was 0.9 (interquartile range [IQR] 0.8-1.0). Independent predictors for a low EQ-5D were age > 66 years (OR 1.49; 95%CI 1.08-2.06), female gender (2.11; 1.55-2.86), hypertension (1.73; 1.03-2.93), peripheral neuropathy (1.62; 0.93-2.84) and clinically relevant depression (11.01; 3.97-30.50). There was no influence of dysglycaemia on the EQ-5D score.
  
  
  CONCLUSIONS
  The present study suggests, that co-morbidity but not average glycaemic control reduces health related quality of life in type 2 diabetes mellitus.
authors.affiliation: Lehrstuhl für Medizinmanagement, Universität Duisburg-Essen, Essen, Germany.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Wasem
authors.forename: Peter
authors.initials: P
authors.lastname: Bramlage
authors.forename: Anselm K
authors.initials: AK
authors.lastname: Gitt
authors.forename: Christiane
authors.initials: C
authors.lastname: Binz
authors.forename: Michael
authors.initials: M
authors.lastname: Krekler
authors.forename: Evelin
authors.initials: E
authors.lastname: Deeg
authors.forename: Diethelm
authors.initials: D
authors.lastname: Tschöpe
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology; D012042:Registries; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents